Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2026 04:53 ET | Source: Research and Markets

Pharmaceuticals and Biopharmaceuticals Stability Testing Course: ICH Q1A-Q1F + ICH Q1E + ICH Q5C + EU/CPMP & WHO Guidelines and New ICH Q1 (Draft) (ONLINE EVENT: May 20th - May 22nd, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Stability Testing of Pharmaceuticals and Biopharmaceuticals (May 20th - May 22nd, 2026)" training has been added to ResearchAndMarkets.com's...
April 14, 2026 04:25 ET | Source: Research and Markets

Modern Agile Leadership for Pharma and Biopharma Professionals: Adapting to a Changing Workplace - Practical Leadership Techniques to Maximise Team Performance (ONLINE EVENT: May 11th-12th, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Modern Agile Leadership for Pharma and Biopharma Professionals: Adapting to a Changing Workplace (May 11th - May 12th, 2026)" training has been added...
April 14, 2026 04:14 ET | Source: Research and Markets

Chemistry, Manufacture and Control (CMC) Regulatory Requirements for Biological Drug Products (ONLINE COURSE: Apr 23rd - Apr 24th, 2026)

Dublin, April 14, 2026 (GLOBE NEWSWIRE) -- The "Chemistry, Manufacture and Control (CMC) - Regulatory Requirements for Biological Drug Products (Apr 23rd - Apr 24th, 2026)" training has been added...
April 09, 2026 06:05 ET | Source: Research and Markets

$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Biopharmaceutical CXO Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Biopharmaceutical CXO...
April 07, 2026 10:06 ET | Source: Research and Markets

Bio/Pharmaceutical Outsourcing Report, February 2026: Latest Business Conditions, New Outsourcing Contracts, Opportunity Assessment, Threats for Manufacturers, Mergers, Acquisitions, and Financing

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Bio/Pharmaceutical Outsourcing Report, February 2026" report has been added to ResearchAndMarkets.com's offering.The Bio/Pharmaceutical Outsourcing...
March 31, 2026 08:45 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

PONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and...
March 03, 2026 09:30 ET | Source: Research and Markets

Microbiome Market Competitive Landscape Report 2026: Comprehensive Insights About 140+ Companies and 180+ Drugs

Dublin, March 03, 2026 (GLOBE NEWSWIRE) -- The "Microbiome - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers a detailed analysis of over 140...
March 02, 2026 08:00 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX inhibition beyond HIT PONTE VEDRA, Fla.,...
February 24, 2026 08:30 ET | Source: Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase...
February 20, 2026 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Announces Expanded IP Coverage, Strengthening Position in Biotech Evolution

NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...